In addition, considering the robust real-life experience on the safety and efficacy of voretigene neparvovec treatment for biallelic RPE65-retinopathy, which offered insights on the unexpected occurrence of chorioretinal atrophy in treated patients, it seems to be of utmost importance to carefully select the patients who will be included in a future phase 1 clinical trial on the basis of FAF patterns.29 Here, RPE65 is linked to retinal disorder.